Market Access

Pharma company claims that the IRA’s drug pricing clauses violate the First and Fifth Amendments.

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.

The latest on its implementation—and the implications for biopharma.

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.

How current frameworks influence coverage decisions and pricing negotiations.

The products, cloud revenue management solution provider says, are aimed at addressing supply chain challenges.

Cost Plus Drug Co. adds J&J's Janssen medications to its offerings, increasing affordability for diabetes patients.

How various factors are affecting the amount of funds allocated to healthcare.

Pharma Commerce provides a look into a few of the conference’s highlights.

AmerisourceBergen exec explains how his experience in health policy analysis and data analytics helps him tackle patient access obstacles.

AmerisourceBergen exec dives into the shift in Medicare Part D patient requirements.

New Pharma Commerce column addresses the relevance of pricing.

Semiannual update includes better revenue forecasting and state reporting

Exploring the legislation's diverging requirements between regulatory agencies and global payers, and its impact on the commercial results of biopharma companies

Agreement featuring UK pharma services consultancy intends to grow PharmaLex's pan-European market access presence

While all drug development efforts are fraught with peril, a growing number of biopharma companies—large and small—are staking a claim in the rare disease treatment space, chasing odds that could yield clinical and financial rewards